Pharmaceutical compounds
US7781433B2 · kind B2 · utility
51Cited by
11References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2007 |
| Grant date | Aug 24, 2010 |
| Priority date | — |
| Expiry date | Nov 27, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A thienopyrimidine of formula (I):and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110α subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.